Kenalog®-40 (triamcinolone acetonide) – First-time generic

- On December 12, 2017, Amneal Biosciences announced the FDA approval of an AP-rated generic version of Bristol-Myers Squibb's Kenalog-40 (triamcinolone acetonide) injection.
    - Amneal Biosciences' generic Kenalog-40 is poised to launch.
- When oral therapy is not feasible, Kenalog-40 is indicated for intramuscular use for the following conditions: allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmic diseases, renal diseases, respiratory diseases, rheumatic disorders, and some miscellaneous disease states such as trichinosis and tuberculous meningitis under certain conditions.
    - Consult the Kenalog-40 drug label for more detailed indication information.
- Kenalog-40 is also indicated for intra-articular or soft tissue administration as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis.
- Injectable triamcinolone acetonide is also available as the branded product, Kenalog-10.
    - Kenalog-10 carries the same intra-articular or soft tissue administration indications.
    - Consult the Kenalog-10 drug label for additional indications for intralesional administration.
- Annual U.S. sales of Kenalog-40 were $146 million according to October 2017 IQVIA™ market data.